Gephyrin can undergo both S‐nitrosylation and S‐palmitoylation at Cys212 and Cys284.[23] There is competition between these two modifications.[31] The nNOS inhibitor increases protein palmitoylation, while treatment with palmitoylation inhibitors increases protein nitrosylation.[31, 58] In our experiments, we used nNOS inhibitors or genetic silence of nNOS expression to reduce SNO‐gephyrin and improve anxiety‐like behaviors by increasing the membrane expression of GABAAR γ2. The gene discussed is NOS1; the disease is Anxiety.